Christopher Haqq - 01 Jun 2023 Form 3 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role
Exhibit 24.1 - Power of Attorney. Title: Executive Vice President, Head of R&D and Chief Medical Officer
Signature
/s/ Nishant M. Dharia, Attorney-in-fact
Issuer symbol
ELTX
Transactions as of
01 Jun 2023
Net transactions value
$0
Form type
3
Filing time
12 Jun 2023, 17:12:54 UTC
Previous filing
13 Aug 2021
Next filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ELTX Common Stock 31,981 01 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ELTX Stock Option (right to buy) 01 Jun 2023 Common Stock 3,620 $13.81 Direct F1, F2
holding ELTX Stock Option (right to buy) 01 Jun 2023 Common Stock 99,891 $3.87 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of capital stock of the corporation then known as Elicio Therapeutics, Inc. ("Old Elicio") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of January 17, 2023, by and among the Issuer, Arkham Merger Sub, Inc. and Old Elicio (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of capital stock was exchanged for 0.0181 shares of the Issuer's common stock, giving effect to a reverse split of the Issuer's common stock of 10-to-1.
F2 Represents 3,620 stock options granted under the Issuer's 2012 Equity Incentive Plan. Twenty five percent (25%) of the stock options vest on the one-year anniversary of March 23, 2022 with the remaining options vesting in equal monthly installments over a three-year period thereafter.
F3 Represents 99,891 stock options granted under the Issuer's 2022 Equity Incentive Plan. The options vest in equal monthly installments over three years, beginning on November 28, 2022

Remarks:

Exhibit 24.1 - Power of Attorney. Title: Executive Vice President, Head of R&D and Chief Medical Officer